Filing Flows

Filing Flows › Rapport Therapeutics (RAPP) › Next earnings date

Rapport Therapeutics (RAPP) earnings: beat the estimate

Rapport Therapeutics (RAPP) reported on Nov 4, 2026 and beat the EPS estimate: −$0.84 against −$1.22 (+31.2%). It beat the EPS estimate in 60% of the quarters on record.

Last result+31.2% vs estimate
Beat rate60%

The last report

Rapport Therapeutics reported revenue of $20.0M for the first quarter 2026, net loss $19.9M. How it makes money → · Every quarter →

Rapport Therapeutics: EPS against the estimate, last 5 reportsRapport Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.73−$0.71Nov 25−$0.67−$0.72Mar 26−$0.71−$0.42May 26−$0.99−$1.19Aug 26−$1.22−$0.84Nov 26
Latest (Nov 26): Estimate −$1.22, Reported −$0.84.

Rapport Therapeutics' latest quarter

Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Rapport Therapeutics beat earnings?

Rapport Therapeutics (RAPP) reported on Nov 4, 2026 and beat the EPS estimate: −$0.84 against −$1.22 (+31.2%).

When does RAPP report earnings?

The next date is not set yet.

Does Rapport Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.